The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Topic: Drugs - Primary Care

Thursday, 08 September 2016
The American Heart Association has published a scientific statement providing prescribers with a list of drugs that can cause or worsen heart failure. Heart failure patients are usually taking medications for multiple medical conditions with resulting risk for drug-drug or drug-condition interactions.
Category: Have You Heard
Tuesday, 11 April 2017
Painkillers considered harmless by the general public are associated with increased risk of cardiac arrest, according to recent research.
Monday, 21 November 2016
HF has a major impact on patients, their families, the NHS and social care services. It still has a poor prognosis, worse than many of the common cancers that also affect older people. It causes significant morbidity and imposes a major cost burden on the health service. This editorial provides an introduction to a special supplement on a first-in-class oral treatment for heart failure.
Category: Editorial
Tuesday, 11 April 2017
Detailed results from the FOURIER cardiovascular outcomes trial on evolocumab were presented at a late-breaking oral presentation at the American College of Cardiology meeting in Washington DC recently. This is the first major outcomes study to be published for a PCSK9 inhibitor – a new class of cholesterol-lowering medicines.
Monday, 21 November 2016
The UK faces an epidemic of heart failure (HF). NICE guidelines emphasise the importance of multidisciplinary assessment and care by HF specialists, evidence-based prescribing, and careful discharge planning after hospitalisation. This article highlights areas where improvements can be made in the management of HF including taking lessons from the latest National Heart Failure Audit.
Category: Editorial
Monday, 21 November 2016
A number of drug classes are used in the treatment of patients with heart failure. This illustrated Back to Basics poster describes the various drugs and their mechanisms of action to give health care professionals and their patients a greater understanding of heart failure management and where sacubitril/valsartan fits into the picture.
Category: Back to Basics
Thursday, 28 April 2016
Dr David Haslam, chair of the UK’s National Obesity Forum, provides a useful review of SGLT-2 inhibitors and their ability to lower glucose level, body weight and blood pressure in people with type 2 diabetes.
Category: Editorial
Thursday, 08 September 2016
Intensified and multifaceted treatment of patients with type 2 diabetes and poor prognosis due to microalbuminuria extends median lifetime by 8 years compared with conventional therapy, according to a new long-term Danish follow-up study of the Steno-2 trial.
Sunday, 12 March 2017
For the first time the European Commission has approved the use of a diabetes treatment for its effect on both blood sugar and cardiovascular events. Empagliflozin product information now includes data on the reduction of risk of cardiovascular death in addition to data on the improvement of blood sugar control.
Category: Have You Heard
Monday, 17 July 2017
A new study led by the University of Leicester suggests that one in three people who suffer from high blood pressure are failing to take medication as prescribed by their healthcare professionals. Non-adherence to antihypertensive treatment is a critical contributor to suboptimal blood pressure control.
Page 1 of 3

Article search and filter